Esteban J I, López-Talavera J C, Genescà J, Madoz P, Viladomiu L, Muñiz E, Martin-Vega C, Rosell M, Allende H, Vidal X
Liver Unit, Hospital General Universitari Vall d'Hebrón, Barcelona, Spain.
Ann Intern Med. 1991 Sep 15;115(6):443-9. doi: 10.7326/0003-4819-115-6-443.
To determine the epidemiologic, clinical, serologic, and histologic importance of antibodies to hepatitis C virus (anti-HCV) in blood donors.
Cross-sectional identification and prospective evaluation of seropositive donors; retrospective assessment of infectivity; and nested case-control study for risk factors.
Liver unit of a referral-based university hospital.
Of 30,231 consecutive donors, 368 (1.2%) were found to be anti-HCV-reactive by enzyme-linked immunosorbent assay (ELISA). Two hundred and fifty-four of these 368 donors were evaluated for risk factors by comparison with 284 age- and sex-matched controls. Eighty-six spouses of seropositive donors were also evaluated.
Twenty-four percent of the seropositive donors had a history of percutaneous exposure to blood. This rate increased to 45% when only those donors confirmed to be anti-HCV positive by a second-generation recombinant immunoblot assay (RIBA-2) were considered. A family history of liver disease (odds ratio, 2.8; 95% Cl, 1.6 to 4.8), previous blood transfusion (odds ratio, 6.1; 95% Cl, 3 to 12.5), and a history of tattooing or intravenous drug abuse (odds ratio, 8.4; 95% Cl, 2.3 to 31) were associated with anti-HCV seropositivity. An elevated alanine aminotransferase (ALT) level was found in 58% of the seropositive donors. Of the 150 donors tested, 104 (69%; Cl, 62% to 77%) were confirmed by RIBA-2 to be anti-HCV positive. Of the 105 donors who had a biopsy, 16% had normal histologic findings, 11% had minimal changes, 21% had chronic persistent hepatitis, 45% had chronic active hepatitis, and 7% had active cirrhosis. All 77 donors with RIBA-2-confirmed seropositivity had histologic abnormalities. Of 43 donors evaluated in an infectivity study, 82% were implicated in previous HCV transmission. Only 2.3% of the spouses were anti-HCV positive. The ELISA, RIBA-2, and ALT results correlated with infectivity and abnormal histologic findings.
In our geographic area, almost 70% of donors who are anti-HCV positive by ELISA are confirmed to be positive by RIBA-2; most of these donors appear to be chronic carriers of HCV and have substantial liver disease.
确定献血者中丙型肝炎病毒抗体(抗-HCV)的流行病学、临床、血清学及组织学意义。
对血清学阳性献血者进行横断面识别和前瞻性评估;对传染性进行回顾性评估;对危险因素进行巢式病例对照研究。
一所基于转诊的大学医院的肝病科。
在连续的30231名献血者中,368名(1.2%)通过酶联免疫吸附测定(ELISA)检测出抗-HCV反应性。将这368名献血者中的254名与284名年龄和性别匹配的对照进行比较,评估其危险因素。还对86名血清学阳性献血者的配偶进行了评估。
24%的血清学阳性献血者有经皮接触血液史。若仅考虑那些经第二代重组免疫印迹法(RIBA-2)确认为抗-HCV阳性的献血者,这一比例升至45%。肝病家族史(比值比,2.8;95%可信区间,1.6至4.8)、既往输血史(比值比,6.1;95%可信区间,3至12.5)以及纹身或静脉注射毒品史(比值比,8.4;95%可信区间,2.3至31)与抗-HCV血清学阳性相关。58%的血清学阳性献血者丙氨酸氨基转移酶(ALT)水平升高。在150名接受检测的献血者中,104名(69%;可信区间,62%至77%)经RIBA-2确认为抗-HCV阳性。在105名接受活检的献血者中,16%组织学检查结果正常,11%有轻微改变,21%有慢性持续性肝炎,45%有慢性活动性肝炎,7%有活动性肝硬化。所有77名经RIBA-2确认为血清学阳性的献血者均有组织学异常。在一项传染性研究中评估的43名献血者中,82%与既往丙型肝炎病毒传播有关。仅2.3%的配偶抗-HCV阳性。ELISA、RIBA-2和ALT结果与传染性及异常组织学检查结果相关。
在我们所在地区,通过ELISA检测抗-HCV阳性的献血者中,近70%经RIBA-2确认为阳性;这些献血者中的大多数似乎是丙型肝炎病毒的慢性携带者,并有严重肝病。